Pipeline
Development Pipeline
HOME
>
Pipeline
>
Pipeline Overview
We publish the status of our new drug candidates, developed on a complex-systems approach, stage by stage.
This page is intended to communicate the progress of our research and development and to share scientific and academic information. It does not indicate efficacy or effect against any specific disease.
Contents
01
How we approach developmen
03
Stage definitions
02
Pipeline
04
Intellectual property
Contents
01
How we approach development
02
Pipeline
03
Stage definitions
04
Intellectual property
Our Approach
Viewing life as a complex system of interconnected relationships, we run discovery and basic research, manufacturing and CMC, non-clinical work, clinical trials and clinical development, and regulatory submission as one continuous process. Alongside precise analysis of individual elements, we look at multi-component, multi-target and multi-pathway interactions, and carry the knowledge gained at each stage into the next round of scientific validation.
We do not restrict our work to a particular technology or a single mechanism of action. We test scientifically the hypotheses formed from clinical observation and basic research, and develop, stage by stage, those programmes that show promise as new drug candidates.
Pipeline Overview
Discovery and basic research, non-clinical work, manufacturing and CMC, clinical trials and clinical development, and regulatory submission are run as one consistent process. Findings from the clinic and from basic research are validated scientifically and then carried into intellectual property, research collaboration, licensing and clinical development.
Development Pipeline
About Our R&D Pipeline
This page is intended to provide information regarding the research and development status of novel drug candidates at Advalife Science. The drug candidates listed herein include investigational products that have not yet been approved in various countries and regions, including Japan. This information is not intended for the promotion or advertising of pharmaceuticals, nor does it constitute a recommendation for any specific medical treatment. Furthermore, it does not guarantee future regulatory approval, commercialization, efficacy, or safety of the investigational candidates described herein.
What each programme entry covers
Program
Indication
Mechanism of Action
Development Stage
Key Data
CMC
Intellectual Property
Territory & Rights
Partnering Status
Stage Definitions
The stages used in the table above are defined as follows.
Basic research
Discovery of new drug candidates, formation of research hypotheses, and scientific validation of composition, characteristics, mechanism of action and interactions
Non-clinical
Scientific evaluation of pharmacology, safety and related matters required before proceeding to clinical trials
Manufacturing & CMC
Work on process, quality attributes, specifications, stability and formulation, building the manufacturing and quality foundation for clinical development and regulatory submission
Clinical trials and development
Stage-by-stage evaluation of safety, efficacy and other necessary data through clinical trials
Regulatory submission
Consolidation of non-clinical, CMC and clinical data and, following consultation with the regulatory authority, submission for approval as a pharmaceutical product
None of the development programmes described on this page has been approved as a pharmaceutical product. Development status may change as research and testing progress.
Intellectual Property
For the results of our research and development we build an intellectual property strategy for each programme, filing and prosecuting patents on substances and compositions, uses and processes according to the character of the technology and the stage of development.
IP portfolio
Patents, trade marks and know-how relating to our development programmes are managed systematically.
Patents
Granted patents and applications in Japan and elsewhere, including PCT applications, are listed to the extent they can be disclosed.
JP7873525B1
Type / status
Japan · granted / Active
Subject matter
Cancer treatment using extracellular secretion; combination of extracellular secretion with an ascorbic acid component.
Dates
Filed 20 Feb 2025
Published 12 Jun 2026
WO2026176598A1
Type / status
PCT · published
Subject matter
Cancer treatment using extracellular secretion (PCT/JP2025/005920)
Dates
Filed 20 Feb 2025
Published 27 Aug 2026
WO2026177208A1
Type / status
PCT · published
Subject matter
Cancer treatment using BRMs; combination of BRMs with ascorbic acid.
Dates
Priority 20 Feb 2025
Filed 20 Feb 2026
Published 27 Aug 2026
TW202634060A
Type / status
Taiwan · published / Pending
Subject matter
Biological response modifiers (BRMs) and their uses; covering BRMs themselves and a broad range of uses.
Dates
Priority 31 Oct 2024
Filed 31 Oct 2025
Published 16 Aug 2026
* Public information as confirmed on 12 September 2026. The proprietor is General Incorporated Association Advalife Science.
* Patent titles and subject matter follow the published gazettes and do not indicate ef
PIPELINE
Enquiries about our development programmes
Enquiries about in-licensing and licensing are received through our partnering contact point.